Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantSV
SoftBank Vision Fund 2
Activity from announced rounds
Activity in this selectionOct 18, 2026 · Jul 21, 2026
SoftBank Vision Fund 2 is the specified fund explicitly named by Zenity and Encoded.
Recorded funding activity
Zenity secures enterprise agents. Encoded develops neurological gene therapies, while Emergent develops AI software-creation tools. The vehicle remains distinct from Vision Fund 1, SoftBank itself and fund advisers.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $400M 2 disclosed · full round size, not this investor’s share